The company's stock tumbled after it disclosed neuropsychiatric adverse events in unrelated depression studies, even as its lead epilepsy application advances unaffected.
Xenon Pharmaceuticals submitted a New Drug Application to the FDA for azetukalner as an add-on treatment for focal seizures in epilepsy patients, a milestone built on data from its Phase 2b X-TOLE trial and Phase 3 X-TOLE2 trial. In that program, all four doses of azetukalner tested produced statistically significant reductions in monthly seizure frequency compared with placebo, across more than 1,500 patient-years of drug exposure. Two additional Phase 3 epilepsy trials, X-TOLE3 and X-ACKT, continue enrolling patients as normal, meaning the epilepsy program itself has not been interrupted in any way.
The complication sits elsewhere in Xenon's pipeline. The company paused enrollment of new patients in its major depressive disorder and bipolar depression studies, along with their associated open-label extensions, after identifying neuropsychiatric adverse events that had not shown up in its earlier Phase 2 depression study, known as X-NOVA. Patients who were already enrolled in the paused studies remain active in the trials, and the pause applies only to new enrollment going forward. A related depression study, X-NOVA2, is continuing: it has enrolled about 360 of a targeted 450 patients, and Xenon plans to complete the six-week dosing period, unblind the results, and report topline data in the first quarter of 2027.
The market's reaction was severe and immediate. Xenon shares fell as much as 29% intraday before paring losses to close down about 16% for the session, a swing that reflects how quickly investors moved to reprice the psychiatric franchise even though the epilepsy program, which represents the company's most advanced and closely watched asset, was not affected. Xenon's chief executive, Ian Mortimer, said he remains confident in the epilepsy program's efficacy and in its safety and tolerability profile, a distinction the company is clearly trying to keep front and center as the depression news dominates headlines.
The two threads should not be conflated. One is a regulatory submission moving forward on schedule, backed by a large and statistically consistent seizure-reduction dataset. The other is a safety signal that has stopped new enrollment in a chemically related but clinically distinct program, aimed at a different patient population and a different set of endpoints. Investors trying to price Xenon from here need to hold both facts at once rather than letting the depression pause bleed into their view of the epilepsy opportunity, or letting the epilepsy program's progress obscure a real safety question in the psychiatric studies.
What comes next will resolve much of the uncertainty. The FDA's review of the azetukalner NDA will determine whether Xenon has a marketable epilepsy therapy, independent of anything happening in depression. Separately, the topline data from X-NOVA2, expected in the first quarter of 2027, will show whether the adverse events seen in the paused studies also appear in that ongoing trial, which would shape how much of Xenon's psychiatric ambitions survive the scrutiny now underway.